Search Within

Hematologic Malignancies, Division of

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (579)
  2. Journal Article (525)
  3. Research Letter (29)
  4. Review (18)
  5. Guidelines (10)
  6. Book Section (9)
  7. Correspondence (6)
  8. Editorial (6)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Population Sciences Research Program (1185)
  2. Department of Medicine (1184)
  3. Center for Hematologic Malignancies (1003)
  4. Lymphoma (719)
  5. Epidemiology and Biostatistics (483)
  6. Survivorship Research (471)

More Groups

People
  1. Steven Horwitz (644)
  2. Alison Moskowitz (220)
  3. Andrew Zelenetz (177)
  4. Paul Hamlin (140)
  5. Ariela Noy (139)
  6. Andriy Derkach (138)

More People

Years
  1. 2025 (24)
  2. 2024 (85)
  3. 2023 (130)
  4. 2022 (102)
  5. 2021 (101)
  6. 2020 (100)

More Years

Publications
  1. Blood (325)
  2. Journal of Clinical Oncology (158)
  3. Clinical Lymphoma, Myeloma and Leukemia (40)
  4. Hematological Oncology (38)
  5. Blood Advances (29)
  6. Leukemia and Lymphoma (26)

More Publications

Publishers
  1. American Society of Hematology (357)
  2. American Society of Clinical Oncology (168)
  3. Elsevier Inc. (87)
  4. Wiley Blackwell (70)
  5. Nature Publishing Group (59)
  6. American Association for Cancer Research (46)

More Publishers

Results (1185)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prevalence of germline alterations on targeted tumor-normal sequencing of esophagogastric cancer
    Journal Article

    Ku, G. Y.; Kemel, Y.; Maron, S. B.; Chou, J. F.; Ravichandran, V.; Shameer, Z.; Maio, A.; Won, E. S.; Kelsen, D. P.; Ilson, D. H.; more...
    JAMA Network Open (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • First‐in‐human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS‐3201b) in patients with relapsed or refractory non‐Hodgkin lymphomas
    Meeting Abstract

    Ishitsuka, K.; Izutsu, K.; Maruyama, D.; Makita, S.; Jacobsen, E. D.; Horwitz, S.; Kusumoto, S.; Allen, P.; Porcu, P.; Imaizumi, Y.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Cardiotoxicity risk in patients with non‐Hodgkin lymphoma receiving epoch after prior anthracycline exposure
    Meeting Abstract

    Buege, M. J.; Dao, P. H.; Drill, E.; Horwitz, S. M.; LeVoir, A.; Pak, T.; Peterson, T. J.; Matasar, M. J.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Preliminary activity of devimistat (CPI 613) in patients with relapsed or refractory Burkitt lymphoma/leukemia
    Meeting Abstract

    Nikolaenko, L.; Pardee, T. S.; Steiner, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez-Rivera, I.; Straus, D.; Luther, S.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T‐cell lymphoma with less than 10% CD30 expression (SGN35‐032, trial in progress)
    Meeting Abstract

    Jagadeesh, D.; Knowles, S.; Horwitz, S. M.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study
    Journal Article

    Hamadani, M.; Collins, G. P.; Caimi, P. F.; Samaniego, F.; Spira, A.; Davies, A.; Radford, J.; Menne, T.; Karnad, A.; Zain, J. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save